Shares of biotech Sarepta soar 40% after approval for most expensive treatment in the world
Shares in cancer-test developer trading in low volumes ahead of spin-off demanded by antitrust regulators
Critics of plan include green activists, farmers, biotech start-ups and multinationals
Two developers of drugs for inflammatory diseases are latest to disregard poor performance of newly listed companies
Non-binding vote on psychedelic drug will carry weight with FDA in blow to pharmaceutical developers
US decision hands biotech group its first regulatory blessing since its blockbuster Covid-19 jab
US group hopes EyeBio will refill its pipeline with treatments targeting causes of blindness
Merck, GSK and AstraZeneca have all signed deals
Genmab argues ‘anti-Chinese sentiment’ should not deter dealmaking
Machine intelligence is not yet a substitute for the experimentation that underpins understanding of a disease
Agreement worth up to $1.2bn includes plan for combined flu and Covid shots
The UK is a world leader in finding new treatments to tackle diseases
Biosecure Act would prohibit American companies receiving federal grant money from working with some Chinese groups
Ochre Bio partnering with Germany’s Boehringer Ingelheim on treatments that will harness the organ’s capacity to regenerate
WuXi AppTec and WuXi Biologics under threat from proposed national security legislation
It aims to exploit its extraordinary cache of genetic data but changing corporate DNA is hard
Aardvark Therapeutics’ drug has been shown in trials to suppress cravings in patients with rare genetic form of obesity
Danish group seeks to branch out from diabetes and weight loss drugs with Cardior acquisition
Madrigal is the first to win approval for a treatment for a liver disease that affects one in 20
Advocate general of bloc’s top court says decision against world’s biggest gene sequencing group should be annulled
Funding needed to drive innovation and make therapies available to all, says co-discoverer Jennifer Doudna
Acquisition gives pharmaceutical group mid-stage asset to challenge Novartis in new form of cancer care
GHO Capital has put contract research group FairJourney Biologics up for sale
Baseimmune aims to predict future pathogen mutations to create jabs that will be effective for longer
Drug developers raised $6bn in January, helped by a rebound in merger activity
UK Edition
